SNOA Fundamental Analysis - SONOMA PHARMACEUTICALS INC

Name: SONOMA PHARMACEUTICALS INC (SNOA) Stock
Brand: SONOMA PHARMACEUTICALS INC
Rating: 5 (3 reviews)

Fundamental Rating

Overall SNOA gets a fundamental rating of 2 out of 10. We evaluated SNOA against 192 industry peers in the Pharmaceuticals industry. SNOA may be in some trouble as it scores bad on both profitability and health. SNOA is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

SNOA had negative earnings in the past year.

In the past year SNOA has reported a negative cash flow from operations.

SNOA had negative earnings in each of the past 5 years.

In the past 5 years SNOA always reported negative operating cash flow.

1.2 Ratios

SNOA has a Return On Assets of -24.36%. This is comparable to the rest of the industry: SNOA outperforms 56.77% of its industry peers.

Looking at the Return On Equity, with a value of -87.65%, SNOA is in line with its industry, outperforming 44.27% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.36%
ROE	-87.65%
ROIC	N/A

ROA(3y)-29.93%

ROA(5y)-28.63%

ROE(3y)-73.9%

ROE(5y)-70.78%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SNOA's Gross Margin of 37.71% is fine compared to the rest of the industry. SNOA outperforms 60.94% of its industry peers.

In the last couple of years the Gross Margin of SNOA has declined.

The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	37.71%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.69%

GM growth 5Y-3.32%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, SNOA has more shares outstanding

The number of shares outstanding for SNOA has been reduced compared to 5 years ago.

Compared to 1 year ago, SNOA has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -17.84, we must say that SNOA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of SNOA (-17.84) is worse than 80.73% of its industry peers.

SNOA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of SNOA (0.03) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	-17.84

ROIC/WACCN/A

WACC8.72%

2.3 Liquidity

A Current Ratio of 2.70 indicates that SNOA has no problem at all paying its short term obligations.

SNOA has a Current ratio (2.70) which is comparable to the rest of the industry.

SNOA has a Quick Ratio of 1.92. This is a normal value and indicates that SNOA is financially healthy and should not expect problems in meeting its short term obligations.

SNOA's Quick ratio of 1.92 is in line compared to the rest of the industry. SNOA outperforms 44.27% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.7
Quick Ratio	1.92

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.64% over the past year.

Looking at the last year, SNOA shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.

Measured over the past years, SNOA shows a decrease in Revenue. The Revenue has been decreasing by -4.44% on average per year.

EPS 1Y (TTM)46.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%45.71%

Revenue 1Y (TTM)17.44%

Revenue growth 3Y4.2%

Revenue growth 5Y-4.44%

Sales Q2Q%18.4%

3.2 Future

The Earnings Per Share is expected to grow by 15.06% on average over the next years. This is quite good.

SNOA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.80% yearly.

EPS Next Y-96.42%

EPS Next 2Y15.06%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year11.38%

Revenue Next 2Y17.8%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SNOA's earnings are expected to grow with 15.06% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.06%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SNOA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (10/30/2025, 8:00:02 PM)

After market: 3.93 -0.02 (-0.51%)

3.95

-0.05 (-1.25%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-05 2025-11-05/amc

Inst Owners6.31%

Inst Owner Change0.45%

Ins Owners1.28%

Ins Owner Change0%

Market Cap6.52M

Revenue(TTM)14.91M

Net Income(TTM)-3555000

Analysts85.71

Price Target15.1 (282.28%)

Short Float %2.81%

Short Ratio0.43

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-9.96%

Min Revenue beat(2)-17.11%

Max Revenue beat(2)-2.81%

Revenue beat(4)0

Avg Revenue beat(4)-11.43%

Min Revenue beat(4)-17.11%

Max Revenue beat(4)-2.81%

Revenue beat(8)0

Avg Revenue beat(8)-14.73%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.44
P/FCF	N/A
P/OCF	N/A
P/B	1.61
P/tB	1.61
EV/EBITDA	N/A

EPS(TTM)-2.46

EYN/A

EPS(NY)-0.46

Fwd EYN/A

FCF(TTM)-0.83

FCFYN/A

OCF(TTM)-0.72

OCFYN/A

SpS9.04

BVpS2.46

TBVpS2.46

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.36%
ROE	-87.65%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	37.71%
FCFM	N/A

ROA(3y)-29.93%

ROA(5y)-28.63%

ROE(3y)-73.9%

ROE(5y)-70.78%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.69%

GM growth 5Y-3.32%

F-Score4

Asset Turnover1.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	134.07%
Cap/Sales	1.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.7
Quick Ratio	1.92
Altman-Z	-17.84

F-Score4

WACC8.72%

ROIC/WACCN/A

Cap/Depr(3y)91.77%

Cap/Depr(5y)85.45%

Cap/Sales(3y)0.91%

Cap/Sales(5y)0.96%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)46.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%45.71%

EPS Next Y-96.42%

EPS Next 2Y15.06%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)17.44%

Revenue growth 3Y4.2%

Revenue growth 5Y-4.44%

Sales Q2Q%18.4%

Revenue Next Year11.38%

Revenue Next 2Y17.8%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y20.94%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y73.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y75.39%

OCF growth 3YN/A

OCF growth 5YN/A

SONOMA PHARMACEUTICALS INC / SNOA FAQ

What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SNOA.

What is the valuation status for SNOA stock?

ChartMill assigns a valuation rating of 0 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.

Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?

SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SONOMA PHARMACEUTICALS INC / SNOA FAQ

What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?

What is the valuation status for SNOA stock?

Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?